PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2186
- Registration Number
- NCT00683800
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Study of Different Doses of a Novel Treatment for Onychomycosis
- Conditions
- Distal, Subungual Onychomycosis
- Interventions
- Drug: AN2690, 2.5%Drug: AN2690, 5%Drug: AN2690, 7.5%Drug: Vehicle
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00679770
- Locations
- 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸DermResearch, Inc., Austin, Texas, United States
🇺🇸Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC, San Antonio, Texas, United States
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00680134
- Locations
- 🇺🇸
Academic Dermatology Associates, Albuquerque, New Mexico, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸DermResearch, Inc., Austin, Texas, United States
Study of Different Doses of a Novel Treatment for Onychomycosis
- Conditions
- Distal, Subungual Onychomycosis
- Interventions
- Drug: AN2690, 2.5%Drug: AN2690, 5%Drug: AN2690, 7.5%Drug: AN2690 Solution Vehicle
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 159
- Registration Number
- NCT00679965
- Locations
- 🇲🇽
Unidad de Investigación en Salud (UIS), Chihuahua, Mexico
🇲🇽Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
🇲🇽Instituto Dermatologico Jalisciense, Guadalajara, Mexico
Cumulative Irritation Test
- Conditions
- Onychomycosis
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00680095
- Locations
- 🇺🇸
The Education and Research Foundation, Inc., Lynchburg, Virginia, United States
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
- Conditions
- Onychomycosis
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT00680160
- Locations
- 🇺🇸
J&S Studies, Bryan, Texas, United States
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
- Conditions
- Onychomycosis
- Interventions
- Drug: AN2690 Solution, 5.0%Drug: AN2690 Solution, 7.5%
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00679523
- Locations
- 🇲🇽
MIRC / OCA Hospital, Monterrey, Mexico
🇲🇽Instituto Dermatologico Jalisciense, Guadalajara, Mexico
🇲🇽IMIC, Mexico City, Mexico
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
- Conditions
- Onychomycosis
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00679601
- Locations
- 🇺🇸
J&S Studies, Bryan, Texas, United States
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 723
- Registration Number
- NCT00678392
- Locations
- 🇺🇸
LAC-USC Medical Center, Los Angeles, California, United States
🇺🇸Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
- Conditions
- Malaria, Falciparum
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00677833
- Locations
- 🇲🇱
Pfizer Investigational Site, Sikasso, West Africa, Mali